TY  - JOUR
AU  - Dorontić, Slađana
AU  - Bonasera, Aurelio
AU  - Scopelliti, Michelangelo
AU  - Marković, Olivera
AU  - Verbić, Tatjana
AU  - Sredojević, Dušan
AU  - Ciasca, Gabriele
AU  - Di Santo, Riccardo
AU  - Mead, James L.
AU  - Budimir, Milica
AU  - Bajuk-Bogdanović, Danica
AU  - Mojsin, Marija
AU  - Pejić, Jelena
AU  - Stevanović, Milena
AU  - Jovanović, Svetlana
PY  - 2024
UR  - https://www.sciencedirect.com/science/article/pii/S221334372401323X
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2396
AB  - The widespread usage of the herbicide glyphosate calls for urgent action, aiming at the development of new, simple, low-cost, and eco-friendly detection approaches. In the last decade, investigation of graphene quantum dots (GQDs) as potential optical probes for various pollutants rapidly grew, thanks to their easy-manipulative structure, remarkable photoluminescence (PL) in the visible part of the spectrum, good dispersibility, biocompatibility, and non-toxicity, as well. Herein, a fast, simple, and environmentally friendly method for GQDs structural modification is presented. GQDs raw powder was exposed to γ- rays at three different doses (100, 200, and 300 kGy) in air, without any solvent or reagents. Irradiation of dots under such affordable conditions led to the additional incorporation of oxygen-containing moieties in the GQD structure. For the first time, oxygen-rich GQDs irradiated at a 300 kGy dose were successfully applied as direct turn-off PL probe for glyphosate detection. The high coefficient of determination (R-squared (R2) = 0.99) and very low limit of detection (3.02 μmol L-1) reveal good linearity between the potential sensor and analyte, as well as sensitivity. Glyphosate was successfully detected in celery samples, with a recovery value of 107 ± 0.85%. To evaluate the biological safety of the proposed sensing probe, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) and the hemolysis assays were performed. Obtained results show that irradiated and non-irradiated GQDs did not cause the death of MRC-5 cells, and hemolysis of erythrocytes. The obtained results demonstrate that GQDs irradiated in an air medium can be potentially applied for glyphosate detection.
PB  - Elsevier
T2  - Journal of Environmental Chemical Engineering
T1  - High-performing structural optimization of graphene quantum dots as glyphosate herbicide photoluminescent probes: real case studies and mechanism insights
IS  - 4
SP  - 113193
VL  - 12
DO  - 10.1016/j.jece.2024.113193
ER  - 

@article{
author = "Dorontić, Slađana and Bonasera, Aurelio and Scopelliti, Michelangelo and Marković, Olivera and Verbić, Tatjana and Sredojević, Dušan and Ciasca, Gabriele and Di Santo, Riccardo and Mead, James L. and Budimir, Milica and Bajuk-Bogdanović, Danica and Mojsin, Marija and Pejić, Jelena and Stevanović, Milena and Jovanović, Svetlana",
year = "2024",
abstract = "The widespread usage of the herbicide glyphosate calls for urgent action, aiming at the development of new, simple, low-cost, and eco-friendly detection approaches. In the last decade, investigation of graphene quantum dots (GQDs) as potential optical probes for various pollutants rapidly grew, thanks to their easy-manipulative structure, remarkable photoluminescence (PL) in the visible part of the spectrum, good dispersibility, biocompatibility, and non-toxicity, as well. Herein, a fast, simple, and environmentally friendly method for GQDs structural modification is presented. GQDs raw powder was exposed to γ- rays at three different doses (100, 200, and 300 kGy) in air, without any solvent or reagents. Irradiation of dots under such affordable conditions led to the additional incorporation of oxygen-containing moieties in the GQD structure. For the first time, oxygen-rich GQDs irradiated at a 300 kGy dose were successfully applied as direct turn-off PL probe for glyphosate detection. The high coefficient of determination (R-squared (R2) = 0.99) and very low limit of detection (3.02 μmol L-1) reveal good linearity between the potential sensor and analyte, as well as sensitivity. Glyphosate was successfully detected in celery samples, with a recovery value of 107 ± 0.85%. To evaluate the biological safety of the proposed sensing probe, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) and the hemolysis assays were performed. Obtained results show that irradiated and non-irradiated GQDs did not cause the death of MRC-5 cells, and hemolysis of erythrocytes. The obtained results demonstrate that GQDs irradiated in an air medium can be potentially applied for glyphosate detection.",
publisher = "Elsevier",
journal = "Journal of Environmental Chemical Engineering",
title = "High-performing structural optimization of graphene quantum dots as glyphosate herbicide photoluminescent probes: real case studies and mechanism insights",
number = "4",
pages = "113193",
volume = "12",
doi = "10.1016/j.jece.2024.113193"
}

Dorontić, S., Bonasera, A., Scopelliti, M., Marković, O., Verbić, T., Sredojević, D., Ciasca, G., Di Santo, R., Mead, J. L., Budimir, M., Bajuk-Bogdanović, D., Mojsin, M., Pejić, J., Stevanović, M.,& Jovanović, S.. (2024). High-performing structural optimization of graphene quantum dots as glyphosate herbicide photoluminescent probes: real case studies and mechanism insights. in Journal of Environmental Chemical Engineering
Elsevier., 12(4), 113193.
https://doi.org/10.1016/j.jece.2024.113193

Dorontić S, Bonasera A, Scopelliti M, Marković O, Verbić T, Sredojević D, Ciasca G, Di Santo R, Mead JL, Budimir M, Bajuk-Bogdanović D, Mojsin M, Pejić J, Stevanović M, Jovanović S. High-performing structural optimization of graphene quantum dots as glyphosate herbicide photoluminescent probes: real case studies and mechanism insights. in Journal of Environmental Chemical Engineering. 2024;12(4):113193.
doi:10.1016/j.jece.2024.113193 .

Dorontić, Slađana, Bonasera, Aurelio, Scopelliti, Michelangelo, Marković, Olivera, Verbić, Tatjana, Sredojević, Dušan, Ciasca, Gabriele, Di Santo, Riccardo, Mead, James L., Budimir, Milica, Bajuk-Bogdanović, Danica, Mojsin, Marija, Pejić, Jelena, Stevanović, Milena, Jovanović, Svetlana, "High-performing structural optimization of graphene quantum dots as glyphosate herbicide photoluminescent probes: real case studies and mechanism insights" in Journal of Environmental Chemical Engineering, 12, no. 4 (2024):113193,
https://doi.org/10.1016/j.jece.2024.113193 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Milenković, Marija
AU  - Basarić, Dusica
AU  - Tomić, Branko
AU  - Marković, Olivera
AU  - Zdravković, Marija
AU  - Ignjatović, Vera
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1516
AB  - Background: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infec-tion, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. Methods: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 pa-tients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020-November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. Results: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with throm-bophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. Conclusion: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection
EP  - 156
SP  - 151
VL  - 218
DO  - 10.1016/j.thromres.2022.08.020
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Milenković, Marija and Basarić, Dusica and Tomić, Branko and Marković, Olivera and Zdravković, Marija and Ignjatović, Vera",
year = "2022",
abstract = "Background: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infec-tion, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. Methods: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 pa-tients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020-November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. Results: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with throm-bophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. Conclusion: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection",
pages = "156-151",
volume = "218",
doi = "10.1016/j.thromres.2022.08.020"
}

Kovač, M., Mitić, G., Milenković, M., Basarić, D., Tomić, B., Marković, O., Zdravković, M.,& Ignjatović, V.. (2022). Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 218, 151-156.
https://doi.org/10.1016/j.thromres.2022.08.020

Kovač M, Mitić G, Milenković M, Basarić D, Tomić B, Marković O, Zdravković M, Ignjatović V. Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection. in Thrombosis Research. 2022;218:151-156.
doi:10.1016/j.thromres.2022.08.020 .

Kovač, Mirjana, Mitić, Gorana, Milenković, Marija, Basarić, Dusica, Tomić, Branko, Marković, Olivera, Zdravković, Marija, Ignjatović, Vera, "Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection" in Thrombosis Research, 218 (2022):151-156,
https://doi.org/10.1016/j.thromres.2022.08.020 . .

TY  - JOUR
AU  - Bila, Jelena
AU  - Sretenović, Aleksandra
AU  - Jelicić, Jelena
AU  - Tošić, Nataša
AU  - Marjanović, Irena
AU  - Fekete, Marija Dencic
AU  - Antić, Darko
AU  - Todorovic-Balint, Milena
AU  - Marković, Olivera
AU  - Milojević, Zoran
AU  - Radojković, Milica
AU  - Trajković, Goran
AU  - Purić, Mila
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/962
AB  - Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
EP  - 615
IS  - 11
SP  - 610
VL  - 16
DO  - 10.1016/j.clml.2016.08.007
ER  - 

@article{
author = "Bila, Jelena and Sretenović, Aleksandra and Jelicić, Jelena and Tošić, Nataša and Marjanović, Irena and Fekete, Marija Dencic and Antić, Darko and Todorovic-Balint, Milena and Marković, Olivera and Milojević, Zoran and Radojković, Milica and Trajković, Goran and Purić, Mila and Pavlović, Sonja and Mihaljević, Biljana",
year = "2016",
abstract = "Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma",
pages = "615-610",
number = "11",
volume = "16",
doi = "10.1016/j.clml.2016.08.007"
}

Bila, J., Sretenović, A., Jelicić, J., Tošić, N., Marjanović, I., Fekete, M. D., Antić, D., Todorovic-Balint, M., Marković, O., Milojević, Z., Radojković, M., Trajković, G., Purić, M., Pavlović, S.,& Mihaljević, B.. (2016). Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 16(11), 610-615.
https://doi.org/10.1016/j.clml.2016.08.007

Bila J, Sretenović A, Jelicić J, Tošić N, Marjanović I, Fekete MD, Antić D, Todorovic-Balint M, Marković O, Milojević Z, Radojković M, Trajković G, Purić M, Pavlović S, Mihaljević B. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia. 2016;16(11):610-615.
doi:10.1016/j.clml.2016.08.007 .

Bila, Jelena, Sretenović, Aleksandra, Jelicić, Jelena, Tošić, Nataša, Marjanović, Irena, Fekete, Marija Dencic, Antić, Darko, Todorovic-Balint, Milena, Marković, Olivera, Milojević, Zoran, Radojković, Milica, Trajković, Goran, Purić, Mila, Pavlović, Sonja, Mihaljević, Biljana, "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma" in Clinical Lymphoma Myeloma & Leukemia, 16, no. 11 (2016):610-615,
https://doi.org/10.1016/j.clml.2016.08.007 . .

TY  - CONF
AU  - Elezović, Ivo
AU  - Antić, Darko
AU  - Miljić, Predrag
AU  - Mitrović, Mirjana
AU  - Đorđević, Valentina
AU  - Stojanović, Ljudmila
AU  - Marković, Olivera
AU  - Kovač, Mirjana
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/592
PB  - Pergamon-Elsevier Science Ltd, Oxford
C3  - Thrombosis Research
T1  - Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery
EP  - S133
SP  - S133
VL  - 130
DO  - 10.1016/j.thromres.2012.08.084
ER  - 

@conference{
author = "Elezović, Ivo and Antić, Darko and Miljić, Predrag and Mitrović, Mirjana and Đorđević, Valentina and Stojanović, Ljudmila and Marković, Olivera and Kovač, Mirjana",
year = "2012",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery",
pages = "S133-S133",
volume = "130",
doi = "10.1016/j.thromres.2012.08.084"
}

Elezović, I., Antić, D., Miljić, P., Mitrović, M., Đorđević, V., Stojanović, L., Marković, O.,& Kovač, M.. (2012). Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 130, S133-S133.
https://doi.org/10.1016/j.thromres.2012.08.084

Elezović I, Antić D, Miljić P, Mitrović M, Đorđević V, Stojanović L, Marković O, Kovač M. Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery. in Thrombosis Research. 2012;130:S133-S133.
doi:10.1016/j.thromres.2012.08.084 .

Elezović, Ivo, Antić, Darko, Miljić, Predrag, Mitrović, Mirjana, Đorđević, Valentina, Stojanović, Ljudmila, Marković, Olivera, Kovač, Mirjana, "Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery" in Thrombosis Research, 130 (2012):S133-S133,
https://doi.org/10.1016/j.thromres.2012.08.084 . .